EUCTR2008-000145-58-IT进行中（未招募）不适用
An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (#8805; 16 to 75 years old) with partial onset seizures with or without secondary generalization. - ND
CB Pharma S.A.0 个研究点目标入组 223 人开始时间: 2008年9月29日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 223
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. An IEC/IRB approved written informed consent signed and dated by the subject or by parent(s) or legal representative. The consent form or a specific assent form, where required, will be signed and dated by minors. 2. Subjects from 16 to 75 years, both inclusive. Subjects under 18 years may only be included where permitted legally and ethically accepted. In Germany, only subjects 18 years and older may be included. 3. Subjects with a body weight ≥ 45 kg. 4. Female subjects without childbearing potential (pre-menarcheal, post-menopausal for at least 2 years, bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible. Female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method. Oral or depot contraceptive treatment with at least 30 µg [or 50 µg ethinylestradiol per intake if associated with carbamazepine (or other strong enzyme inducers e.g. oxcarbazepine)] must be used in conjunction with a barrier method. Monogamous relationship with vasectomized partner or double-barrier contraception are acceptable methods. The subject must understand the consequences and potential risks of inadequately protected sexual activity, be educated about and understand the proper use of contraceptive methods, and undertake to inform the Investigator of any potential change in status. Sexual inactivity might be accepted on a case-by-case basis. 5. Subject/legally acceptable representative considered as reliable and capable of adhering to the protocol (e.g. able to understand and complete diaries), Visit schedule or medication intake according to the judgment of the Investigator. 6. Well-characterized partial onset seizures according to the ILAE classification (1981) or focal epilepsy or epileptic syndrome according to the ILAE classification (1989). 7. Presence of an EEG compatible with the clinical diagnosis of focal epilepsy in the last 5 years. If an EEG has not been performed within the last 5 years, a Baseline EEG must be performed before Visit 3.
- •ADDITIONAL INCLUSION CRITERIA ON SYNOPSIS
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Seizure type IA simple partial non-motor as only seizure type. 2. History or presence of seizures occurring too frequently or indistinctly separated to be reliably counted, during the 6 months preceding Visit 1 or during Baseline. 3. History or presence of status epilepticus during the 1 year preceding Visit 1 or during Baseline. 4. History or presence of pseudo-seizures. 5. Subjects on felbamate with less than 18 months continuous exposure before Visit 1. Subjects having been on felbamate are eligible if the combined duration of treatment and wash-out is ≥ 18 months. 6. Subjects currently on vigabatrin. Subjects having been on vigabatrin if no visual fields examination report available including standard static (Humphrey or Octopus) or cinetic perimetry (Goldman) or if results of these examinations are abnormal. 7. Subjects who have received treatment with phenobarbital or primidone within 3 months prior to Visit 1 and subjects who have received treatment with benzodiazepines within 1 month prior to Visit 1. Subjects with VNS are excluded unless their device has been documented to be inactivated for at least 28 days prior to Visit 1.
- •ADDITIONAL EXCLUSION CRITERIA ON SYNOPSIS
研究者
相似试验
进行中（未招募）
不适用
An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (= 16 to 75 years old) with partial onset seizures with or without secondary generalization.EUCTR2008-000144-14-SECB Inc223
进行中（未招募）
不适用
An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (= 16 to 75 years old) with partial onset seizures with or without secondary generalization.Partial onset seizures with or without secondary generalization.MedDRA version: 9.1Level: LLTClassification code 10015037Term: EpilepsyEUCTR2008-000145-58-FICB Pharma S.A.223
进行中（未招募）
1 期
An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (= 16 to 75 years old) with partial onset seizures with or without secondary generalization.Partial onset seizures with or without secondary generalization.MedDRA version: 9.1Level: LLTClassification code 10015037Term: EpilepsyEUCTR2008-000145-58-FRCB Pharma S.A.62
进行中（未招募）
不适用
An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (= 16 to 75 years old) with partial onset seizures with or without secondary generalization.Partial onset seizures with or without secondary generalization.MedDRA version: 9.1Level: LLTClassification code 10015037Term: EpilepsyEUCTR2008-000144-14-BECB Inc223
进行中（未招募）
不适用
An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (= 16 to 75 years old) with partial onset seizures with or without secondary generalization.EUCTR2008-000145-58-HUCB Pharma S.A.223